Literature DB >> 10393365

Estimating the overlap between sentinel lymph nodes and axillary node samples in breast cancer.

G Cserni1.   

Abstract

Management of the axilla in breast cancer patients is a controversial issue. Axillary sampling and sentinel lymphadenectomy are both conservative surgical approaches which aim to stage the disease. These procedures target selective treatment of node-positive patients and seem to allow the omission of axillary clearance in node-negative ones. In this way, they reduce the rate of complications in an otherwise overtreated subset of patients. Forty consecutive patients with palpable T1 and T2 breast carcinoma underwent sentinel lymphadenectomy following mapping with Patent blue dye, with subsequent axillary clearance and excision of the tumor or mastectomy. Then the largest/firmest 3,4,5 and 6 nodes were selected from all the lymph nodes in order to model an axillary sample. It was suggested that these are the nodes that are the most likely to be included in the specimen during sampling, because of their size and consistency. The probability of the sentinel lymph nodes falling into the sample of the 3-6 largest/firmest nodes was calculated. The sentinel nodes predicted the axillary nodal status in 95%, while the samples of the largest 3, 4, 5 and 6 nodes were predictive in 95, 96, 98 and 98%, respectively. The two methods of evaluation displayed a considerable overlap, as the sentinel node would have been included in the 3 6 largest/firmest nodes in 79 92% of the cases, depending on the number of largest nodes evaluated. The overlap was greater after fine needle aspiration of the primary tumor. Although the two alternative staging procedures of 3, 4, 5 or 6 node sampling and sentinel lymphadenectomy with the vital blue dye technique cannot be simultaneously done without one influencing the other, and the first method was only modeled, the results suggest that there is a considerable overlap between the two; axillary sampling may often remove the sentinel lymph nodes.

Entities:  

Mesh:

Year:  1999        PMID: 10393365     DOI: 10.1053/paor.1999.0174

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  28 in total

Review 1.  Consequences of sentinel node in clinical decision making in breast cancer and prospects for future studies.

Authors:  U Veronesi; S Zurrida; V Galimberti
Journal:  Eur J Surg Oncol       Date:  1998-04       Impact factor: 4.424

Review 2.  The role of the sentinel lymph node in the management of patients with breast cancer.

Authors:  R Statman; A E Giuliano
Journal:  Adv Surg       Date:  1996

3.  Axillary sampling and the risk of erroneous staging of breast cancer. An analysis of 960 consecutive patients.

Authors:  O Mathiesen; J Carl; O Bonderup; J Panduro
Journal:  Acta Oncol       Date:  1990       Impact factor: 4.089

4.  Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.

Authors:  U Veronesi; G Paganelli; V Galimberti; G Viale; S Zurrida; M Bedoni; A Costa; C de Cicco; J G Geraghty; A Luini; V Sacchini; P Veronesi
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

5.  The Edinburgh randomized trial of axillary sampling or clearance after mastectomy.

Authors:  A P Forrest; D Everington; C C McDonald; R J Steele; U Chetty; H J Stewart
Journal:  Br J Surg       Date:  1995-11       Impact factor: 6.939

6.  Assessment of axillary lymph node status.

Authors:  G C Davies; R R Millis; J L Hayward
Journal:  Ann Surg       Date:  1980-08       Impact factor: 12.969

Review 7.  Principles and guidelines for surgeons--management of symptomatic breast cancer. European Society of Surgical Oncology.

Authors:  M Blichert-Toft; M G Smola; L Cataliotti; N O'Higgins
Journal:  Eur J Surg Oncol       Date:  1997-04       Impact factor: 4.424

8.  A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma.

Authors:  C I Kiricuta; J Tausch
Journal:  Cancer       Date:  1992-05-15       Impact factor: 6.860

9.  Patients with early breast cancer benefit from effective axillary treatment.

Authors:  J R Harris; R T Osteen
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

10.  Metastases to the upper levels of the axillary nodes in carcinoma of the breast and its implications for nodal sampling procedures.

Authors:  J Pigott; R Nichols; W A Maddox; C M Balch
Journal:  Surg Gynecol Obstet       Date:  1984-03
View more
  4 in total

1.  The reliability of sampling three to six nodes for staging breast cancer.

Authors:  G Cserni
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

2.  Is Regression after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Different in Sentinel and Non-sentinel Nodes?

Authors:  Gábor Cserni; Tamás Zombori; Xavier Andreu; Simonetta Bianchi; Peter Regitnig; Isabel Amendoeira; Davide Balmativola; Anikó Kovács; Alicia Cordoba; Angelika Reiner; Janina Kulka; Handan Kaya; Inta Liepniece-Karele; Cecily Quinn; Bence Kővári
Journal:  Pathol Oncol Res       Date:  2017-04-08       Impact factor: 3.201

3.  The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis.

Authors:  Sarah Pesek; Taka Ashikaga; Lars Erik Krag; David Krag
Journal:  World J Surg       Date:  2012-09       Impact factor: 3.352

4.  Improved false negative rate of axillary status using sentinel lymph node biopsy and ultrasound-suspicious lymph node sampling in patients with early breast cancer.

Authors:  Yulong Wang; Haiyan Dong; Hongyan Wu; Li Zhang; Kai Yuan; Hongqiang Chen; Mingwen Jiao; Rongzhan Fu
Journal:  BMC Cancer       Date:  2015-05-09       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.